argenx (ENXTBR:ARGX) just released its Q3 2026 results, giving investors a detailed look at how its autoimmune portfolio is translating into revenue, profit and earnings per share.
argenx shares trade at €782.2, with a 7.50% 7 day share price return but a 7.45% decline over the past month. That choppy pattern sits against a longer history where the 1 year total shareholder return is 11.42% and the 5 year total shareholder return is 202.12%, indicating that investors may be weighing recent earnings and pipeline updates against an already very strong multi year run.
Spot opportunities beyond argenx by scanning a hand picked 612 high quality undiscovered gems with strong fundamentals that could be setting up for the next phase of their story.
After a sharp multi year climb and a recent pullback, argenx now trades about 22% below the average analyst target and at a steep discount to some intrinsic value models. So where does fair value really sit?
Most Popular Narrative: 14% Overvalued
Compared with the €782.2 share price, the most followed argenx narrative points to a fair value of €686.43, which implies the stock trades rich to that framework even after the recent pullback.
👉 Reasonable mid-term scenario (2 to 4 years):
• $6 to 10bn potential revenue range
See why 2 investors see argenx as 14% overvalued .
Result: Fair Value of €686.43 (OVERVALUED)
Still, the argenx story can break if key late stage trials disappoint, or if pricing pressure in gMG and CIDP treatment sharply dents profitability expectations.
Find out about the key risks to this argenx narrative .
Another View: argenx Through the P/E Lens
A second lens tells a very different story. On a P/E of 29.2x, argenx trades below peers at 39x, yet above its own fair ratio of 25.8x. That mix of relative discount and internal premium points to valuation risk if expectations reset, or room for upside if execution stays on track.
To see how those earnings multiples align with the broader numbers in more detail, take a look at the valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown. .
Next Steps
The mix of enthusiasm and caution around argenx is clear, so move quickly, review the underlying numbers yourself, then weigh the 4 key rewards and 1 important warning sign .
Looking for more investment ideas beyond argenx?
Do not stop with argenx. Use these targeted filters to surface fresh opportunities that fit your style before the market prices them more fully.
-
Hunt for quality at a discount by scanning a 195 high quality undervalued stocks that screens for strong fundamentals and pricing that still looks conservative.
-
Build a portfolio focused on resilience by checking a 222 resilient stocks with low risk scores that highlights businesses with sturdier financial and risk profiles.
-
Strengthen your income stream by reviewing a 225 dividend fortresses that focuses on higher yielding companies with the potential for more reliable payouts.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ARGX.BR .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
